Viral Hepatitis

You have full text access to this OnlineOpen article

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C†‡

  1. Stefan Zeuzem1,§,*,
  2. Eric M. Yoshida2,
  3. Yves Benhamou3,
  4. Stephen Pianko4,
  5. Vincent G. Bain5,
  6. Daniel Shouval6,
  7. Robert Flisiak7,
  8. Vratislav Rehak8,
  9. Mircea Grigorescu9,
  10. Kelly Kaita10,
  11. Patrick W. Cronin11,
  12. Erik Pulkstenis11,
  13. G. Mani Subramanian11,
  14. John G. McHutchison12

Article first published online: 9 MAY 2008

DOI: 10.1002/hep.22403

Issue

Hepatology

Hepatology

Volume 48, Issue 2, pages 407–417, August 2008

Additional Information

How to Cite

Zeuzem, S., Yoshida, E. M., Benhamou, Y., Pianko, S., Bain, V. G., Shouval, D., Flisiak, R., Rehak, V., Grigorescu, M., Kaita, K., Cronin, P. W., Pulkstenis, E., Subramanian, G. M. and McHutchison, J. G. (2008), Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology, 48: 407–417. doi: 10.1002/hep.22403

Author Information

  1. 1

    J.W. Goethe-University Hospital, Frankfurt, Germany

  2. 2

    University of British Columbia, Vancouver, Canada

  3. 3

    Hôpital Pitié-Salpêtrière, Paris, France

  4. 4

    Monash University Medical School, Victoria, Australia

  5. 5

    University of Alberta, Edmonton, Canada

  6. 6

    Hadassah University, Jerusalem, Israel

  7. 7

    Medical University of Bialystok, Poland

  8. 8

    Spitalul Clinic de Adulti Cluj-Napoca, Romania

  9. 9

    Nuselská Poliklinika–Remedis, Prague, Czech Republic

  10. 10

    University of Manitoba, Winnipeg, Canada

  11. 11

    Human Genome Sciences Inc., Rockville, MD

  12. 12

    Division of Gastroenterology, Duke Clinical Research Institute, Durham, NC

  1. §

    fax: 49-(0)69-6301-6448.

*Direktor der Medizinischen Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany

  1. †

    This study is registered on ClinicalTrials.gov (identifier NCT00115908; http://clinicaltrials.gov/ct2/show/NCT00115908?term=human+genome+sciences&rank=2)

  2. ‡

    Potential conflict of interest: Dr. McHutchison is a consultant for and received grants from Anadys, Colsy Pharmaceutical Group, First Circle Medical, GlaxoSmithKline, Human Genome Sciences, Idenix Pharmaceuticals, Intarcia, Novartis, Pharmasset, Pfizer, Roche, Schering-Plough, Valeant Pharmaceuticals, Vertex Pharmaceuticals, and Wyeth. He received grants from Globe Immune, Medtronics, Salix Pharmaceuticals, and Sanofi-Aventis. He is also a consultant for Biolex, Epiphany Biosciences, InterMune Pharmaceuticals, National Genetics Institute, Peregrine, and United Therapeutics. Drs. Subramanian, Cronin and Pulkstenis own stock in Human Genome Sciences, Inc. Dr. Kaita is a consultant for, is on the speakers' bureau of, and received grants from Schering-Plough, Roche, and Gilead. Dr. Zeuzem is a consultant for, is on the speakers' bureau of, and received grants from Human Genome Sciences, Novartis, Roche, and Schering-Plough. Dr. Yoshida received grants from and advises Hoffmann-La Roche. He also received grants from Schering-Plough, GlaxoSmithKline, Ortho Janssen, Pfizer, Gilead Sciences, and Cangene. He advises Novartis. Dr. Benhamou is a consultant for and is on the speakers' bureau of Human Genome Science and Roche. Dr. Pianko is a consultant for, advises, and is on the speakers' bureau of Human Genome Sciences, Novartis, and Roche. Dr. Bain is a consultant for Human Genome Sciences. Dr. Shouval received grants from Human Genome Sciences. Dr. Flisiak received grants from Debiopharm. He advises and received grants from Human Genome Sciences and Roche.

Publication History

  1. Issue published online: 29 JUL 2008
  2. Article first published online: 9 MAY 2008
  3. Accepted manuscript online: 9 MAY 2008 12:00AM EST
  4. Manuscript Accepted: 25 APR 2008
  5. Manuscript Received: 21 FEB 2008

Funded by

  • Human Genome Sciences Inc., Rockville, MD
  • Novartis Pharma AG, Basel, Switzerland

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (528K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Hong Liang Zhao, Chong Xue, Ji Liang Du, Min Ren, Shan Xia, Zhi Min Liu, Balancing the Pharmacokinetics and Pharmacodynamics of Interferon-α2b and Human Serum Albumin Fusion Protein by Proteolytic or Reductive Cleavage Increases Itsin VivoTherapeutic Efficacy, Molecular Pharmaceutics, 2012, 9, 3, 664

    CrossRef

  2. 2
    S. Pianko, S. Zeuzem, W.-L. Chuang, G. R. Foster, S. K. Sarin, R. Flisiak, C.-M. Lee, P. Andreone, T. Piratvisuth, S. Shah, A. Sood, J. George, M. Gould, P. Komolmit, S. Thongsawat, T. Tanwandee, J. Rasenack, Y. Li, M. Pang, Y. Yin, G. Feutren, I. M. Jacobson, Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3, Journal of Viral Hepatitis, 2012, 19, 6
    Direct Link:
  3. 3
    Kwangwon Hong, Kwangjun Oh, Siyoung Lee, Jaewoo Hong, Jida Choi, Areum Kwak, Dongjun Kang, Eunsom Kim, Seunghyun Jo, Hyunjhung Jhun, Soohyun Kim, Recombinant Fc-IL-18BPc Isoform Inhibits IL-18-Induced Cytokine Production, Hybridoma, 2012, 31, 2, 99

    CrossRef

  4. 4
    B. Ahrén, B. Burke, Using albumin to improve the therapeutic properties of diabetes treatments, Diabetes, Obesity and Metabolism, 2012, 14, 2
    Direct Link:
  5. 5
    McKenzie C. Ferguson, Current Therapies for Chronic Hepatitis C, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011, 31, 1
    Direct Link:
  6. 6
    Joseph Ahn, Steven L. Flamm, Hepatitis C Therapy: Other Players in the Game, Clinics in Liver Disease, 2011, 15, 3, 641

    CrossRef

  7. 7
    Aarthi Chary, Mark Holodniy, Interferon combination therapy for HIV/hepatitis C virus coinfection, Immunotherapy, 2011, 3, 9, 1087

    CrossRef

  8. 8
    Scott J. Bergman, McKenzie C. Ferguson, Cathy Santanello, Interferons as Therapeutic Agents for Infectious Diseases, Infectious Disease Clinics of North America, 2011, 25, 4, 819

    CrossRef

  9. 9
    Jianmin Li, Bing Li, Jun Zhang, Lihua Hou, Changming Yu, Ling Fu, Xiaohong Song, Ting Yu, Jinglong Zhang, Jun Ren, Chun’e Xu, Wei Chen, Preparation of CHO cell-derived rhIFN-ω-Fc with improved pharmacokinetics, Antiviral Research, 2011, 89, 3, 199

    CrossRef

  10. 10
    Peter Ferenci, Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future, Expert Opinion on Drug Safety, 2011, 10, 4, 529

    CrossRef

  11. 11
    Francesco Negro, Adverse effects of drugs in the treatment of viral hepatitis, Best Practice & Research Clinical Gastroenterology, 2010, 24, 2, 183

    CrossRef

  12. 12
    Stefan Zeuzem, Mark S. Sulkowski, Eric J. Lawitz, Vinod K. Rustgi, Maribel Rodriguez–Torres, Bruce R. Bacon, Mircea Grigorescu, Alan D. Tice, Yoav Lurie, Janusz Cianciara, Andrew J. Muir, Patrick W. Cronin, Erik Pulkstenis, G. Mani Subramanian, John G. McHutchison, Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1, Gastroenterology, 2010, 139, 4, 1257

    CrossRef

  13. 13
    David R. Nelson, Yves Benhamou, Wan–Long Chuang, Eric J. Lawitz, Maribel Rodriguez–Torres, Robert Flisiak, Jens W.F. Rasenack, Wiesław Kryczka, Chuan–Mo Lee, Vincent G. Bain, Stephen Pianko, Keyur Patel, Patrick W. Cronin, Erik Pulkstenis, G. Mani Subramanian, John G. McHutchison, Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3, Gastroenterology, 2010, 139, 4, 1267

    CrossRef

  14. 14
    A. Walker, G. Dunlevy, D. Rycroft, P. Topley, L. J. Holt, T. Herbert, M. Davies, F. Cook, S. Holmes, L. Jespers, C. Herring, Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon, Protein Engineering Design and Selection, 2010, 23, 4, 271

    CrossRef

  15. 15
    G Brook, J Main, M Nelson, S Bhagani, E Wilkins, C Leen, M Fisher, Y Gilleece, R Gilson, A Freedman, R Kulasegaram, K Agarwal, C Sabin, C Deacon-Adams, British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010, HIV Medicine, 2010, 11, 1
    Direct Link:
  16. 16
    Kai Lin, Development of novel antiviral therapies for hepatitis C virus, Virologica Sinica, 2010, 25, 4, 246

    CrossRef

  17. 17
    Ayse Aytaman, Marina Kaufman, Norah A Terrault, Management of posttransplant hepatitis C infection, Current Opinion in Organ Transplantation, 2010, 15, 3, 301

    CrossRef

  18. 18
    Timothy T. Kuo, Kristi Baker, Masaru Yoshida, Shuo-Wang Qiao, Victoria G. Aveson, Wayne I. Lencer, Richard S. Blumberg, Neonatal Fc Receptor: From Immunity to Therapeutics, Journal of Clinical Immunology, 2010, 30, 6, 777

    CrossRef

  19. 19
    K. Seden, D. Back, S. Khoo, New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals, Journal of Antimicrobial Chemotherapy, 2010, 65, 6, 1079

    CrossRef

  20. 20
    P. Spagnolo, S. Zeuzem, L. Richeldi, R. M. Du Bois, The complex interrelationships between chronic lung and liver disease: a review, Journal of Viral Hepatitis, 2010, 17, 6
    Direct Link:
  21. 21
    Jun Su, Richard A. Brook, Nathan L. Kleinman, Patricia Corey-Lisle, The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs, Hepatology, 2010, 52, 2
    Direct Link:
  22. 22
    Paul J. Pockros, Why Do We Need Another Interferon?, Gastroenterology, 2010, 139, 4, 1084

    CrossRef

  23. 23
    Geoff McCaughan, Advances in viral hepatitis: 50 years of Australian gastroenterology, Journal of Gastroenterology and Hepatology, 2009, 24,
    Direct Link:
  24. 24
    Vinod K. Rustgi, Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C, Current Medical Research and Opinion, 2009, 25, 4, 991

    CrossRef

  25. 25
    P. Marcellin, Hépatite C : la guérison, Gastroentérologie Clinique et Biologique, 2009, 33, 8-9, 819

    CrossRef

  26. 26
    Kimberly A. Forde, K. Rajender Reddy, Hepatitis C Virus Infection and Immunomodulatory Therapies, Clinics in Liver Disease, 2009, 13, 3, 391

    CrossRef

  27. 27
    Volker Meier, Giuliano Ramadori, Hepatitis C virus virology and new treatment targets, Expert Review of Anti-infective Therapy, 2009, 7, 3, 329

    CrossRef

  28. 28
    Arema A. Pereira, Ira M. Jacobson, New and experimental therapies for HCV, Nature Reviews Gastroenterology & Hepatology, 2009, 6, 7, 403

    CrossRef

  29. 29
    Virginia Clark, David R. Nelson, Novel Interferons for Treatment of Hepatitis C Virus, Clinics in Liver Disease, 2009, 13, 3, 351

    CrossRef

  30. 30
    Avidan U. Neumann, Stephen Pianko, Stefan Zeuzem, Eric M. Yoshida, Yves Benhamou, Moshe Mishan, John G. McHutchison, Erik Pulkstenis, G. Mani Subramanian, Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C, Journal of Hepatology, 2009, 51, 1, 21

    CrossRef

  31. You have free access to this content31
    A. J. V. THOMPSON, J. G. MCHUTCHISON, Review article: investigational agents for chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2009, 29, 7
    Direct Link:
  32. 32
    Fred F Poordad, Grace Chee, Taribavirin: a potential alternative to ribavirin, Future Virology, 2009, 4, 2, 113

    CrossRef

  33. 33
    Ming-Lung Yu, Wan-Long Chuang, Treatment of chronic hepatitis C in Asia: When East meets West, Journal of Gastroenterology and Hepatology, 2009, 24, 3
    Direct Link:
  34. 34
    Bulent Degertekin, Anna SF Lok, Update on viral hepatitis: 2008, Current Opinion in Gastroenterology, 2009, 25, 3, 180

    CrossRef

  35. 35
    Markus Reiser, Virushepatitis B und C, Medizinische Klinik, 2009, 104, 5, 356

    CrossRef

  36. 36
    P. Ferenci, Peginterferon and ribavirin in HCV: Improvement of sustained viral response, Best Practice & Research Clinical Gastroenterology, 2008, 22, 6, 1109

    CrossRef

  37. 37
    Sandro Vento, Francesca Cainelli, Zelalem Temesgen, Perspectives in therapy for hepatitis C, Expert Opinion on Investigational Drugs, 2008, 17, 11, 1635

    CrossRef

  38. 38
    Hubert J. Metzner, Thomas Weimer, Stefan Schulte, Half-Life Extension by Fusion to Recombinant Albumin,
    Direct Link:
View Full Article (HTML) Get PDF (528K)